Ketamine Infusions for Major Depression Disorder

Phase NA interventional

Ketamine, an NMDA antagonist with rapid antidepressant effects, has shown rapid improvement in TRD in prior uncontrolled and controlled studies; single subanaesthetic IV doses (0.5 mg/kg) produce responses lasting up to 72 hours in many patients.

This single-group study offers IV ketamine infusions to patients with treatment-resistant major depression at Sheba Medical Center, following published protocols; safety and clinical response will be monitored.

Sheba MC — Ramat Gan, Israel

Inclusion Criteria:
Diagnosis of Major Depressive Disorder, chronic and/or recurrent of at least moderate severity, reflected by baseline IDS-C30 score ≥32
Insufficient response to ≥2 adequate antidepressant trials in the current episode

Exclusion Criteria:
Current psychotic or dissociative symptoms
Severe personality disorder with psychosis or dissociative symptoms
Lifetime history of psychotic mania
Substance use disorder
Current suicidal ideation
Uncontrolled elevated blood pressure, non-sinus rhythm, unstable ischemic heart disease, uncorrected hyperthyroidism, and for women, pregnancy or initiation of female hormonal treatment <3 months

Start: 2014-01-08

End: 2017-01-08

Company

Product

Legal

Detailed Description

Study Arms & Interventions

Ketamine

Interventions

Participants

Locations

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators